383 related articles for article (PubMed ID: 26642378)
1. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
Barone P; Pignataro R; Garozzo MT; Leonardi S
Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
[TBL] [Abstract][Full Text] [Related]
2. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
3. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
Herlin T
Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
[TBL] [Abstract][Full Text] [Related]
6. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
[TBL] [Abstract][Full Text] [Related]
7. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.
Yokota S; Miyamae T; Imagawa T; Katakura S; Kurosawa R; Mori M
Clin Rev Allergy Immunol; 2005 Jun; 28(3):231-8. PubMed ID: 16129907
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
[TBL] [Abstract][Full Text] [Related]
9. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
10. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.
Woo P; Wilkinson N; Prieur AM; Southwood T; Leone V; Livermore P; Wythe H; Thomson D; Kishimoto T
Arthritis Res Ther; 2005; 7(6):R1281-8. PubMed ID: 16277681
[TBL] [Abstract][Full Text] [Related]
11. [Tocilizumab].
Amano K
Nihon Rinsho; 2013 Jul; 71(7):1238-42. PubMed ID: 23961673
[TBL] [Abstract][Full Text] [Related]
12. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for treating juvenile idiopathic arthritis.
Turnier JL; Brunner HI
Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of blocking IL-6 receptor.
Mima T; Nishimoto N
Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
Imagawa T; Yokota S; Mori M; Miyamae T; Takei S; Imanaka H; Nerome Y; Iwata N; Murata T; Miyoshi M; Nishimoto N; Kishimoto T
Mod Rheumatol; 2012 Feb; 22(1):109-15. PubMed ID: 21667343
[TBL] [Abstract][Full Text] [Related]
16. [Tocilizumab in rheumatoid arthritis].
Rueda Gotor J; Blanco Alonso R
Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab (Actemra).
Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
[TBL] [Abstract][Full Text] [Related]
18. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
Miyamae T; Yokoya S; Yamanaka H; Yokota S
Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
[TBL] [Abstract][Full Text] [Related]
19. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
